Announcement • Apr 18
TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 3 billion in funding from Nuon Co., Ltd. On April 17, 2026. TELCON RF PHARMACEUTICAL. Inc. announced that it has closed the transaction. New Risk • Apr 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩28.1b market cap, or US$19.1m). Announcement • Apr 09
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 3 billion in funding from Nuon Co., Ltd. TELCON RF PHARMACEUTICAL. Inc. has announced to issue 3,000,000 common stock at a price of KRW 1000 per share for gross proceeds of KRW 3,000,000,000 on April 7, 2026. The transaction include investor participation from Nuon Co., Ltd. The transaction has been approved by board of directors. The transaction is expected to close on April 17, 2026. All the securities issued pursuant to the offering is subject to hold period of one year. Announcement • Mar 06
TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 27, 2026 TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 27, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 205, goan-ro 51beon-gil, baegam-myeon, cheoin-gu, gyeonggi-do, yongin South Korea Announcement • Aug 13
TELCON RF PHARMACEUTICAL. Inc. has completed a Follow-on Equity Offering in the amount of KRW 41.504364 billion. TELCON RF PHARMACEUTICAL. Inc. has completed a Follow-on Equity Offering in the amount of KRW 41.504364 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 10,822,520
Price\Range: KRW 3835
Discount Per Security: KRW 95.875
Transaction Features: Rights Offering New Risk • May 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩39.7b market cap, or US$28.9m). Announcement • Mar 12
TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 26, 2025 TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 205, goan-ro 51beon-gil, cheoin-gu, gyeonggi-do, yongin South Korea New Risk • Dec 10
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩7.19b (US$5.02m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₩7.19b market cap, or US$5.02m). Minor Risk Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Announcement • Nov 12
ABION Inc. (KOSDAQ:A203400) agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) for KRW 20.1 billion. ABION Inc. (KOSDAQ:A203400) agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) for KRW 20.1 billion on November 11, 2024. The consideration consist of issue of 2.42 million common stock of ABION Inc. (KOSDAQ:A203400). The expected completion of the transaction is December 16, 2024. New Risk • May 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (₩84.7b market cap, or US$62.4m). Valuation Update With 7 Day Price Move • May 24
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩736, the stock trades at a trailing P/E ratio of 5.9x. Average trailing P/E is 15x in the Electronic industry in South Korea. Total loss to shareholders of 85% over the past three years. Reported Earnings • Mar 23
Full year 2023 earnings released: EPS: ₩124 (vs ₩397 loss in FY 2022) Full year 2023 results: EPS: ₩124 (up from ₩397 loss in FY 2022). Revenue: ₩36.3b (up 31% from FY 2022). Net income: ₩13.9b (up ₩56.0b from FY 2022). Profit margin: 38% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩818, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 17x in the Electronic industry in South Korea. Total loss to shareholders of 86% over the past three years. Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩994, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 17x in the Electronic industry in South Korea. Total loss to shareholders of 85% over the past three years. New Risk • Nov 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Market cap is less than US$100m (₩109.3b market cap, or US$83.3m). Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improves as stock rises 42% After last week's 42% share price gain to ₩977, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 15x in the Electronic industry in South Korea. Total loss to shareholders of 84% over the past three years. Is New 90 Day High Low • Feb 24
New 90-day low: ₩4,890 The company is down 23% from its price of ₩6,360 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 29% over the same period. Is New 90 Day High Low • Jan 28
New 90-day low: ₩5,160 The company is down 14% from its price of ₩6,010 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 56% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: ₩5,490 The company is down 31% from its price of ₩7,920 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 37% over the same period. Is New 90 Day High Low • Dec 23
New 90-day low: ₩5,810 The company is down 42% from its price of ₩9,990 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 15% over the same period. Announcement • Nov 05
Telcon RF Pharmaceutical Inc. announced that it has received KRW 40.65 billion in funding from Hanil Vacuum Co., Ltd. Telcon RF Pharmaceutical Inc. (KOSDAQ:A200230) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 4,290,000,000, series 17 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 22,000,000,000, and series 18 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 14,360,000,000, for aggregate gross proceeds of KRW 40,650,000,000 on November 3, 2020. The transaction will include participation from returning investor Hanil Vacuum Co., Ltd. (KOSDAQ:A123840) for the series 16 and 17 bonds and Evercore Investment Holdings for series 18 bonds. All the bonds carry a coupon rate of 3% and yield to maturity of 5%, and will mature on November 3, 2023. The series 16 bonds are fully convertible into 636,781 shares at a conversion price of KRW 6,737 per share which represents 0.74% stake in the company; the series 17 bonds are fully convertible into 3,265,548 shares at a conversion price of KRW 6,737 per share which represents 3.68% stake; and the series 18 bonds are fully convertible into 2,131,512 shares at a conversion price of KRW 6,737 per share which represents 2.43% stake. The conversion for all the bonds period starts from November 3, 2021 to October 3, 2023. The bonds have a hold period of one year. The transaction has been approved by the board of the directors of the company. Announcement • Sep 29
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 30 billion in funding from Emmaus Life Sciences, Inc. TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) announced a private placement to issue series 15 non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 30,000,000,000 on September 28, 2020. The transaction will include participation from returning investor Emmaus Life Sciences, Inc. (OTCPK:EMMA). The bonds carry a coupon rate and interest rate to maturity of 2.1%, and will mature on October 16, 2030. Interest to be paid every three months deferred to the interest payment date every three months from the day after the issue of the bond to the due date of repayment of the principal. The bonds are 100% convertible into 3,249,566 shares at a conversion price of KRW 9,232 per share which represents 3.80% stake in the company. The conversion period starts from October 16, 2021 and end on September 16, 2030. The bonds have a hold period of one year. The transaction is expected to close on October 16, 2020. The transaction has been approved by the board of the directors.